WellCare Health Plans 10-Q 7 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	6-May-15
Document and Entity Information [Abstract]
Entity Registrant Name	WELLCARE HEALTH PLANS, INC.
Entity Central Index Key	1279363
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		44,042,025
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) (USD $)	3 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Revenues:
Premium	$3,466	$2,975.10
Investment and other income	3.9	10.6
Total revenues	3,469.90	2,985.70
Expenses:
Medical benefits	3,052.20	2,629.90
Selling, general and administrative	256.9	245.3
Deferred ACA fee amortization	58.3	32.3
Medicaid premium taxes	20	17.1
Depreciation and amortization	16.8	14.6
Interest	11.3	9.2
Total expenses	3,415.50	2,948.40
Income from operations	54.4	37.3
Bargain purchase gain	0	28.3
Income before income taxes	54.4	65.6
Income tax expense	36.9	21.5
Net income	17.5	44.1
Other comprehensive income, before tax:
Change in net unrealized gains and losses on available-for-sale securities	0.4	0.2
Income tax expense (benefit) related to other comprehensive income	0.1	-0.1
Other comprehensive income, net of tax	0.3	0.3
Comprehensive income	$17.80	$44.40
Net income per common share:
Basic net income per share (in dollars per share)	$0.40	$1.01
Diluted net income per share (in dollars per share)	$0.39	$1
Weighted average common shares outstanding:
Basic (in shares)	43,981,977	43,802,047
Diluted (in shares)	44,304,006	44,123,791

CONSOLIDATED_BALANCE_SHEETS_Un

CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Current Assets:
Cash and cash equivalents	$1,172.90	$1,313.50
Investments	207.1	172.8
Premiums receivable, net	735.4	609
Pharmacy rebates receivable, net	408.1	358.9
Receivables from government partners	88.5	83
Funds receivable for the benefit of members	779.8	781.5
Deferred ACA industry fee	174.5	0
Income taxes receivable	0.3	0
Prepaid expenses and other current assets, net	116.2	170.5
Deferred income tax asset	27.9	37.1
Total current assets	3,710.70	3,526.30
Property, equipment and capitalized software, net	211.3	187.1
Goodwill	263.2	263.2
Other intangible assets, net	98.2	101
Long-term investments	215.5	257.3
Restricted investments	162.5	150.3
Other assets	9.2	9.8
Total Assets	4,670.60	4,495
Current Liabilities:
Medical benefits payable	1,454.60	1,483.80
Unearned premiums	5	86.9
ACA industry fee liability	232.8	0
Accounts payable	27.7	18.9
Other accrued expenses and liabilities	331.2	294.7
Current portion of amount payable related to investigation resolution	0	35.2
Income taxes payable	0	1.9
Other payables to government partners	34.7	14.3
Total current liabilities	2,086	1,935.70
Deferred income tax liability	53	48.4
Long-term debt	900	900
Other liabilities	17.5	15
Total liabilities	3,056.50	2,899.10
Commitments and contingencies (see Note 11)	0	0
Stockholders' Equity:
Preferred stock, $0.01 par value (20,000,000 authorized, no shares issued or outstanding)	0	0
Common stock, $0.01 par value (100,000,000 authorized, 44,041,586 and 43,914,106 shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively)	0.4	0.4
Paid-in capital	503.4	503
Retained earnings	1,110.60	1,093.10
Accumulated other comprehensive loss	-0.3	-0.6
Total Stockholders' Equity	1,614.10	1,595.90
Total Liabilities and Stockholders' Equity	$4,670.60	$4,495

CONSOLIDATED_BALANCE_SHEETS_Un1

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Stockholders' Equity:
Preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, authorized (in shares)	20,000,000	20,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, authorized (in shares)	100,000,000	100,000,000
Common stock, issued (in shares)	44,041,586	43,914,106
Common stock, outstanding (in shares)	44,041,586	43,914,106

CONSOLIDATED_STATEMENT_OF_CHAN

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) (USD $)	Total	Common Stock [Member]	Paid in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Loss [Member]
In Millions, except Share data, unless otherwise specified
Balance at Dec. 31, 2014	$1,595.90	$0.40	$503	$1,093.10	($0.60)
Balance (in shares) at Dec. 31, 2014	43,914,106	43,914,106
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued for exercised stock options	0.3	0	0.3	0	0
Common stock issued for exercised stock options (in shares)		8,020
Common stock issued for vested restricted stock, restricted stock units and performance stock units	0	0	0	0	0
Common stock issued for vested restricted stock, restricted stock units, performance stock units and market stock units (in shares)		178,840
Repurchase and retirement of shares to satisfy tax withholding requirements	-5.2	0	-5.2	0	0
Repurchase and retirement of shares to satisfy tax withholding requirements (shares)		-59,380
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	4.1	0	4.1	0	0
Incremental tax benefit from equity-based compensation	1.2	0	1.2	0	0
Comprehensive income	17.8	0	0	17.5	0.3
Balance at Mar. 31, 2015	$1,614.10	$0.40	$503.40	$1,110.60	($0.30)
Balance (in shares) at Mar. 31, 2015	44,041,586	44,041,586

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash used in operating activities:
Net income	$17.50	$44.10
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation and amortization	16.8	14.6
Equity-based compensation expense	4.1	1.2
Bargain purchase gain	0	-28.3
Deferred ACA fee amortization	58.3	32.3
Incremental tax benefit from equity-based compensation	-1.2	-0.2
Deferred taxes, net	13.7	5.9
Provision for doubtful receivables	3.7	3.7
Changes in operating accounts, net of effects from acquisitions:
Premiums receivable, net	-130.1	-33.1
Pharmacy rebates receivable, net	-49.2	-34.6
Prepaid expenses and other current assets, net	54.3	17.2
Medical benefits payable	-29.2	51.1
Unearned premiums	-81.9	-0.5
Accounts payable and other accrued expenses	41.8	35.3
Other payables to government partners	14.9	-99.7
Amount payable related to investigation resolution	-35.2	-35.9
Income taxes receivable/payable, net	-1	12.3
Other, net	2.8	0.7
Net cash used in operating activities	-99.9	-13.9
Cash (used in) provided by investing activities:
Acquisitions, net of cash acquired	0	164.2
Purchases of investments	-20.4	-90.6
Proceeds from sale and maturities of investments	28.2	107.9
Purchases of restricted investments	-14	-12.3
Proceeds from maturities of restricted investments	1.9	6.3
Additions to property, equipment and capitalized software, net	-35.8	-13.2
Net cash (used in) provided by investing activities	-40.1	162.3
Cash (used in) provided by financing activities:
Proceeds from exercises of stock options	0.3	0.2
Incremental tax benefit from equity-based compensation	1.2	0.2
Repurchase and retirement of shares to satisfy tax withholding requirements	-5.2	-2.2
Payments on capital leases	-0.1	-0.4
Funds receivable for the benefit of members, net	3.2	29.6
Net cash (used in) provided by financing activities	-0.6	27.4
(Decrease) increase in cash and cash equivalents	-140.6	175.8
Balance at beginning of period	1,313.50	1,482.50
Balance at end of period	1,172.90	1,658.30
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for taxes	20.7	3.3
Cash paid for interest	2.7	0.2
SUPPLEMENTAL DISCLOSURES OF NON-CASH TRANSACTIONS:
Non-cash additions to property, equipment, and capitalized software	$2.40	$2.10

ORGANIZATION_BASIS_OF_PRESENTA

ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES	ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES
	WellCare Health Plans, Inc. (the "Company," "we," "us," or "our"), provides managed care services for government-sponsored health care coverage with a focus on Medicaid and Medicare programs. As of March 31, 2015, we served approximately 3.8 million members. During the three months ended March 31, 2015, we operated Medicaid health plans in Florida, Georgia, Hawaii, Illinois, Kentucky, Missouri, New Jersey, New York and South Carolina. As of March 31, 2015, we also operated Medicare Advantage ("MA") coordinated care plans ("CCPs") in Arkansas, California, Connecticut, Florida, Georgia, Hawaii, Illinois, Kentucky, Louisiana, Mississippi, New Jersey, New York, South Carolina, Tennessee and Texas, as well as stand-alone Medicare prescription drug plans ("PDP") in 49 states and the District of Columbia.
	Basis of Presentation and Use of Estimates
	The accompanying unaudited condensed consolidated balance sheets and statements of comprehensive income, changes in stockholders' equity, and cash flows include the accounts of the Company and all of its majority-owned subsidiaries. We eliminated all intercompany accounts and transactions.
	The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. The accompanying unaudited condensed consolidated interim financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the fiscal year ended December 31, 2014 included in our Annual Report on Form 10-K, filed with the U.S. Securities and Exchange Commission in February 2015. Results for the interim periods presented are not necessarily indicative of results that may be expected for the entire year or any other interim period.
	In the opinion of management, the interim financial statements reflect all normal recurring adjustments that we consider necessary for the fair presentation of our financial position, results of operations and cash flows for the interim periods presented. In accordance with GAAP, we make certain estimates and assumptions that affect the amounts reported in the condensed consolidated interim financial statements and accompanying notes. We base these estimates on our knowledge of current events and anticipated future events and evaluate and update our assumptions and estimates on an ongoing basis; however, actual results may differ from our estimates. We evaluated all material events subsequent to the date of these condensed consolidated interim financial statements.
	Significant Accounting Policies
	Medical Benefits and Medical Benefits Payable
	We recognize the cost of medical benefits in the period in which services are provided, including an estimate of the cost of medical benefits incurred but not reported ("IBNR"). Medical benefits expense includes direct medical expenses and certain medically-related administrative costs. We evaluate our estimates of medical benefits payable as we obtain more complete claims information and medical expense trend data over time. We record differences between actual experience and estimates used to establish the liability, which we refer to as favorable and unfavorable prior year reserve developments, as increases or decreases to medical benefits expense in the period we identify the differences.
	Favorable prior year reserve development amounted to $12.1 million for the three months ended March 31, 2015, compared to $32.5 million of unfavorable prior year reserve development recognized for the three months ended March 31, 2014. Such amounts are net of the development relating to refunds associated with minimum medical loss ratio provisions. The favorable development recognized in the three months ended March 31, 2015 was due mainly to lower than projected medical costs, while the unfavorable development recognized in 2014 was primarily due to higher than expected medical services in our Medicare Health Plan segment and to a lesser extent, the Medicaid Health Plans segment, that was not discernible until the impact became clearer over time as claim payments were processed.
	ACA Industry Fee
	In 2014, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the "ACA") began imposing an annual premium-based health insurance industry assessment (the "ACA industry fee") on health insurers. The total ACA industry fee levied on the health insurance industry was $8 billion in 2014 and will be $11.3 billion in 2015, with increasing annual amounts thereafter, growing to $14.3 billion by 2018. After 2018, the ACA industry fee increases according to an index based on net premium growth. The ACA industry fee is not deductible for income tax purposes. For 2015, we accrued the initial estimated liability of $232.8 million as of January 1, 2015, with a corresponding deferred expense asset that is being amortized to expense on a straight line basis. We incurred approximately $58.3 million and $32.3 million of such amortization as ACA industry fee expense in the three months ended March 31, 2015 and 2014, respectively. The deferred expense asset amounted to $174.5 million at March 31, 2015 and is reported as 'Deferred ACA industry fee' on the condensed consolidated balance sheet. The 2015 final fee amount will be determined in August 2015 and our estimate is subject to change.
	We have obtained amendments, written agreements and other documentation from our Medicaid customers to reimburse us for the impact of the industry fee on our Medicaid plans for 2015, including its non-deductibility for income tax purposes.
	Consequently, we recognized $54.4 million of reimbursement for the ACA industry fee as premium revenue in the three months ended March 31, 2015, compared to $23.6 million recognized during the same period in 2014.
	Recently Issued Accounting Standards
	In April 2015, the Financial Accounting Standards Board ("FASB") issued ASU 2015-03, "Interest - Imputation of Interest (Subtopic 835-30) - Simplifying the Presentation of Debt Issuance Costs" to simplify the presentation of debt issuance costs by requiring debt issuance costs to be presented as a deduction from the corresponding debt liability. This will make the presentation of debt issuance costs consistent with the presentation of debt discounts or premiums. For public business entities, the final guidance will be effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. We will adopt this guidance effective January 1, 2016. We do not believe the adoption of this standard will have a material impact on our consolidated financial position, results of operations or cash flows.

ACQUISITIONS

ACQUISITIONS	3 Months Ended
	Mar. 31, 2015
Business Combinations [Abstract]
ACQUISITIONS	ACQUISITIONS
	Windsor
	On January 1, 2014, we acquired all of the outstanding stock of Windsor Health Group, Inc. ("Windsor") from Munich Health North America, Inc., a part of Munich Re Group. We included the results of Windsor's operations from the date of acquisition in our consolidated financial statements. Windsor’s operations contributed premium revenue of $144.0 million and $167.6 million for the three months ended March 31, 2015 and 2014, respectively.
	We completed certain aspects of the accounting for the Windsor acquisition during the fourth quarter of 2014, and based on the final purchase price allocation, we allocated $195.3 million of the purchase price to identified tangible net assets and $54.3 million of the purchase price to identified intangible assets. The weighted average amortization period for the intangible assets was 11.5 years.
	Based on the final purchase price allocation, the fair value of the net tangible and intangible assets that we acquired exceeded the total consideration paid or payable to the seller by $29.5 million, which was recognized as a bargain purchase gain for the year ended December 31, 2014. We recognized $28.3 million of the bargain purchase gain in the three months ended March 31, 2014.

SEGMENT_REPORTING

SEGMENT REPORTING	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
SEGMENT REPORTING	SEGMENT REPORTING
	On a regular basis, we evaluate discrete financial information and assess the performance of our three reportable segments, Medicaid Health Plans, Medicare Health Plans and Medicare PDPs, to determine the most appropriate use and allocation of Company resources.
	Medicaid Health Plans
	Our Medicaid Health Plans segment includes plans for beneficiaries of Temporary Assistance for Needy Families ("TANF"), Supplemental Security Income ("SSI"), Aged Blind and Disabled ("ABD") and other state-based programs that are not part of the Medicaid program, such as Children's Health Insurance Program ("CHIP") and Managed Long-Term Care ("MLTC") programs. TANF generally provides assistance to low-income families with children. ABD and SSI generally provide assistance to low-income aged, blind or disabled individuals. CHIP programs provide assistance to qualifying families who are not eligible for Medicaid because their incomes exceed the applicable income thresholds. The MLTC program is designed to help people with chronic illnesses or who have disabilities and need health and long-term care services, such as home care or adult day care, to enable them to stay in their homes and communities as long as possible.
	Our Medicaid operations in certain states individually account for 10% or more of our consolidated premium revenue. Those states, and the respective Medicaid premium revenue as a percentage of total consolidated premium revenue, are as follows:
		For the Three Months Ended March 31,
		2015		2014
	Kentucky	18%		17%
	Florida	16%		10%
	Georgia	12%		12%
	Our primary Kentucky contract commenced in July 2011, has an initial three-year term and provides for four additional one-year option terms, exercisable upon mutual agreement of the parties, which potentially extends the total term until July 2018. The first option term, through June 30, 2015, has been exercised. In April 2015, the Kentucky Cabinet for Health and Family Services Department of Medicaid Services issued a request for proposal for its Medicaid program in Kentucky for services commencing on July 1, 2015. Responses are currently due on May 22, 2015, and we are currently in the process of preparing our response.
	The Georgia Department of Community Health (the "Georgia DCH") exercised its option in June 2014 to extend the term of our Georgia Medicaid contract until June 30, 2015. There is one remaining one-year option term, exercisable by the Georgia DCH, which would potentially extend the contract term to June 30, 2016. In February 2015, the Georgia Department of Community Health issued a request for proposals for its Medicaid program, under which services would commence on July 1, 2016. Responses are currently due on May 14, 2015, and we are currently in the process of preparing our response.
	In February 2014, we executed a contract with the Florida Agency for Health Care Administration ("AHCA") pursuant to which our Staywell health plan participates in eight out of the state's 11 regions under the Managed Medical Assistance Program ("MMA"), which was fully implemented as of August 2014. The contract expires on December 31, 2018. Our 2012-2015 Florida Medicaid contracts were terminated early in connection with the implementation of the new program.
	Medicare Health Plans
	Our Medicare Health Plans reportable segment includes the combined operations of both the MA and Medicare Supplement operating segments. Medicare is a federal program that provides eligible persons age 65 and over and some disabled persons with a variety of hospital, medical and prescription drug benefits. MA is Medicare's managed care alternative to the original Medicare program, which provides individuals standard Medicare benefits directly through the Centers for Medicare & Medicaid Services ("CMS"). Our MA CCPs generally require members to seek health care services and select a primary care physician from a network of health care providers. In addition, we offer coverage of prescription drug benefits under the Medicare Part D program as a component of most of our MA plans. We also offer Medicare Supplement policies in certain states.
	Medicare PDPs
	We offer stand-alone Medicare Part D coverage to Medicare-eligible beneficiaries in our Medicare PDPs segment. The Medicare Part D prescription drug benefit is supported by risk sharing with the federal government through risk corridors designed to limit the losses and gains of the participating drug plans and by reinsurance for catastrophic drug costs. The government subsidy is based on the national weighted average monthly bid for this coverage, adjusted for risk factor payments. Additional subsidies are provided for dually-eligible beneficiaries and specified low-income beneficiaries. The Part D program offers national in-network prescription drug coverage that is subject to limitations in certain circumstances.
	Summary of Financial Information
	We allocate goodwill and other intangible assets to our reportable operating segments. We do not allocate any other assets and liabilities, investment and other income, or selling, general and administrative, depreciation and amortization, or interest expense to our reportable operating segments, with the exception of the ACA industry fee. The Company's decision-makers primarily use premium revenue, medical benefits expense and gross margin to evaluate the performance of our reportable operating segments. A summary of financial information for our reportable operating segments through the gross margin level and a reconciliation to income before income taxes is presented in the tables below.
		For the Three Months Ended March 31,
		2015			2014
	Premium revenue:	(in millions)
	Medicaid Health Plans	$	2,203.10		$	1,638.80
	Medicare Health Plans	983.4			963.3
	Medicare PDPs	279.5			373
	Total premium revenue	3,466.00			2,975.10
	Medical benefits expense:
	Medicaid Health Plans	1,917.60			1,389.30
	Medicare Health Plans	856.4			851.5
	Medicare PDPs	278.2			389.1
	Total medical benefits expense	3,052.20			2,629.90
	ACA industry fee expense:
	Medicaid Health Plans	34.8			18.9
	Medicare Health Plans	17.7			10.7
	Medicare PDPs	5.8			2.7
	Total ACA industry fee expense	58.3			32.3
	Gross margin
	Medicaid Health Plans	250.7			230.6
	Medicare Health Plans	109.3			101.1
	Medicare PDPs	(4.5		)	(18.8		)
	Total gross margin	355.5			312.9
	Investment and other income	3.9			10.6
	Other expenses	(305.0		)	(286.2		)
	Income from operations	$	54.4		$	37.3

NET_INCOME_PER_COMMON_SHARE

NET INCOME PER COMMON SHARE	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
NET INCOME PER COMMON SHARE	NET INCOME PER COMMON SHARE
	We compute basic net income per common share on the basis of the weighted-average number of unrestricted common shares outstanding. We compute diluted net income per common share on the basis of the weighted-average number of unrestricted common shares outstanding plus the dilutive effect of outstanding stock options, restricted stock units ("RSUs"), market stock units ("MSUs") and performance stock units ("PSUs") using the treasury stock method.
	The calculation of the weighted-average common shares outstanding — diluted is as follows:
		For the Three Months Ended March 31,
		2015	2014
	Weighted-average common shares outstanding — basic	43,981,977	43,802,047
	Dilutive effect of:
	Unvested RSUs, MSUs and PSUs	319,662	308,133
	Stock options	2,367	13,611
	Weighted-average common shares outstanding — diluted	44,304,006	44,123,791
	Anti-dilutive stock options, RSUs, MSUs and PSUs excluded from computation	3,520	72,457

INVESTMENTS

INVESTMENTS	3 Months Ended
	Mar. 31, 2015
Investments, Debt and Equity Securities [Abstract]
INVESTMENTS	INVESTMENTS
	The Company considers all of its investments as available-for-sale securities. The amortized cost, gross unrealized gains or losses and estimated fair value of short-term and long-term investments by security type are summarized in the following tables.
		Amortized		Gross		Gross			Estimated
		Cost		Unrealized		Unrealized			Fair Value
				Gains		Losses
	March 31, 2015
	Auction rate securities	$	34.1	$	—	$	(1.8	)	$	32.3
	Corporate debt and other securities	159.2		0.4		(0.2		)	159.4
	Money market funds	41.4		—		—			41.4
	Municipal securities	87.6		0.5		(0.1		)	88
	Variable rate bond fund	85.1		0.1		(0.2		)	85
	U.S. government securities	16.5		0.1		(0.1		)	16.5
		$	423.9	$	1.1	$	(2.4	)	$	422.6
	December 31, 2014
	Auction rate securities	$	34.1	$	—	$	(1.8	)	$	32.3
	Certificates of deposit	0.3		—		—			0.3
	Corporate debt and other securities	162.2		0.1		(0.4		)	161.9
	Money market funds	41.4		—		—			41.4
	Municipal securities	86.9		0.5		(0.1		)	87.3
	Variable rate bond fund	85.1		0.2		(0.1		)	85.2
	U.S. government securities	21.7		0.1		(0.1		)	21.7
		$	431.7	$	0.9	$	(2.5	)	$	430.1
	Realized gains and losses on sales and redemptions of investments were not material for the three months ended March 31, 2015 and 2014.
	Contractual maturities of available-for-sale investments at March 31, 2015 are as follows:
		Total		Within		1 Through 5			5 Through 10		Thereafter
				1 Year		Years			Years
	Auction rate securities	$	32.3	$	—	$	—		$	—	$	32.3
	Corporate debt and other securities	159.4		60.9		97.7			0.3		0.5
	Money market funds	41.4		41.4		—			—		—
	Municipal securities	88		18.6		56.8			11.1		1.5
	Variable rate bond fund	85		85		—			—		—
	U.S. government securities	16.5		1.2		15.3			—		—
		$	422.6	$	207.1	$	169.8		$	11.4	$	34.3
	Actual maturities may differ from contractual maturities due to the exercise of pre-payment options.
	Excluding investments in U.S. government securities, we are not exposed to any significant concentration of credit risk in our fixed maturities portfolio. Our long-term investments include $32.3 million estimated fair value of municipal note securities with an auction reset feature ("auction rate securities"), which were issued by various state and local municipal entities for the purpose of financing student loans, public projects and other activities. Liquidity for these auction rate securities is typically provided by an auction process, which allows holders to sell their notes and resets the applicable interest rate at pre-determined intervals, usually every seven or 35 days. We consider our auction rate securities to be in an inactive market as auctions have continued to fail in 2015. Our auction rate securities have been in an unrealized loss position for more than twelve months. Two auction rate securities with an aggregate par value of $22.5 million have investment grade security credit ratings and one auction rate security with a par value of $11.6 million has a credit rating below investment grade. Our auction rate securities are covered by government guarantees or municipal bond insurance and we have the ability and intent to hold these securities until maturity or market stability is restored. Accordingly, we do not believe our auction rate securities are impaired and have not recorded any other-than-temporary impairment as of March 31, 2015.
	There were no redemptions or sales of our auction rate securities during the three months ended March 31, 2015 and 2014, and accordingly, gains and losses associated with our auction rate securities were not material during any of those periods.

RESTRICTED_INVESTMENTS

RESTRICTED INVESTMENTS	3 Months Ended
	Mar. 31, 2015
Restricted Investments Note [Abstract]
RESTRICTED INVESTMENTS	RESTRICTED INVESTMENTS
	The amortized cost, gross unrealized gains, gross unrealized losses and fair value of our restricted investment securities are as follows:
		Amortized		Gross		Gross			Estimated
		Cost		Unrealized		Unrealized			Fair Value
				Gains		Losses
	March 31, 2015
	Cash	$	64.1	$	—	$	—		$	64.1
	Certificates of deposit	1.1		—		—			1.1
	Money market funds	65.8		—		—			65.8
	U.S. government securities	31.4		0.1		—			31.5
		$	162.4	$	0.1	$	—		$	162.5
	December 31, 2014
	Cash	$	53.3	$	—	$	—		$	53.3
	Certificates of deposit	1		—		—			1
	Money market funds	65.9		—		—			65.9
	U.S. government securities	30.1		0.1		(0.1		)	30.1
		$	150.3	$	0.1	$	(0.1	)	$	150.3
	Realized gains and losses on restricted investments were immaterial for the three months ended March 31, 2015 and 2014.

EQUITYBASED_COMPENSATION

EQUITY-BASED COMPENSATION	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
EQUITY-BASED COMPENSATION	EQUITY-BASED COMPENSATION
	Compensation expense related to our equity-based compensation awards was $4.1 million and $1.2 million for the three months ended March 31, 2015 and 2014, respectively. As of March 31, 2015, there was $22.5 million of unrecognized compensation cost related to non-vested equity-based compensation arrangements that is expected to be recognized over a weighted-average period of 1.6 years. The unrecognized compensation cost for our PSUs, which are subject to variable accounting, was determined based on the closing common stock price of $91.46 as of March 31, 2015 and amounted to approximately $10.7 million of the total unrecognized compensation. Due to the nature of the accounting for these awards, future compensation cost will fluctuate based on changes in our common stock price.
	A summary of stock option activity for the three months ended March 31, 2015 is presented in the table below.
		Shares		Weighted
				Average
				Exercise
				Price
	Outstanding as of January 1, 2015	8,020		$	38.92
	Granted	—		—
	Exercised	(8,020	)	38.92
	Forfeited and expired	—		—
	Outstanding as of March 31, 2015	—		$	—
	A summary of RSU, PSU and MSU award activity for the three months ended March 31, 2015 is presented in the table below.
		RSUs		PSUs		MSUs		Total
	Outstanding as of January 1, 2015	406,903		395,075		113,663		915,641
	Granted	3,520		—		9,361		12,881
	Vested	(128,145	)	(18,548	)	(32,494	)	(179,187	)
	Forfeited and expired	(11,378	)	(75,253	)	(7,022	)	(93,653	)
	Outstanding as of March 31, 2015	270,900		301,274		83,508		655,682
	The weighted-average grant-date fair value of all equity awards granted during the three months ended March 31, 2015 was $77.79.

DEBT

DEBT	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
DEBT	DEBT
	As of March 31, 2015, our outstanding debt included a $300.0 million term loan (the "Term Loan") outstanding under our existing credit agreement (the "Credit Agreement") and $600.0 million 5.75% unsecured senior notes due 2020 (the "Senior Notes"). The Credit Agreement also provides for a senior unsecured revolving loan facility (the “Revolving Credit Facility”) of up to $300.0 million, which may be used for general corporate purposes of the Company and its subsidiaries. Borrowings under the Credit Agreement bear interest at a rate of LIBOR plus a spread between 1.50% and 2.625%, or a rate equal to the prime rate plus a spread between 0.50% to 1.625%, depending upon our cash flow leverage ratio (which is defined as the ratio of our total debt to total consolidated EBITDA.) Unutilized commitments under the Credit Agreement are subject to a fee of 0.25% to 0.45% depending upon our cash flow leverage ratio. The interest rate on the Term Loan was 2.25% as of March 31, 2015.
	The Credit Agreement contains negative and financial covenants that limit certain activities of the Company and its subsidiaries, including (i) restrictions on our ability to incur additional indebtedness; and (ii) financial covenants that require (a) the cash flow leverage ratio not to exceed a maximum; (b) a minimum interest expense and principal payment coverage ratio; and (c) 105% of our required level of statutory net worth for our health maintenance organization and insurance subsidiaries. The Credit Agreement also contains customary representations and warranties that must be accurate in order for us to borrow under the Revolving Credit Facility. In addition, the Credit Agreement contains customary events of default. If an event of default occurs and is continuing, we may be required immediately to repay all amounts outstanding under the Credit Agreement. Lenders holding at least 50% of the loans and commitments under the Credit Agreement may elect to accelerate the maturity of the loans and/or terminate the commitments under the Credit Agreement upon the occurrence and during the continuation of an event of default.
	The Senior Notes were issued under an indenture, dated as of November 14, 2013 (the “Base Indenture”), as supplemented by the First Supplemental Indenture, dated as of November 14, 2013 (the “First Supplemental Indenture” and, together with the Base Indenture, the “Indenture”) each between us and The Bank of New York Mellon Trust Company, N.A., as trustee. The indenture under which the Senior Notes were issued contain covenants that, among other things, limit our ability and the ability of our restricted subsidiaries to:
	•	incur additional indebtedness and issue preferred stock;
	•	pay dividends or make other distributions;
	•	make other restricted payments and investments;
	•	sell assets, including capital stock of restricted subsidiaries;
	•	create certain liens;
	•	incur restrictions on the ability of restricted subsidiaries to pay dividends or make other payments, and in the case of the our subsidiaries, guarantee indebtedness;
	•	engage in transactions with affiliates;
	•	create unrestricted subsidiaries; and
	•	merge or consolidate with other entities.
	As of March 31, 2015 and as of the date of this filing, we remain in compliance with all covenants under both the Credit Agreement and the Senior Notes.

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS
	Our condensed consolidated balance sheets include the following financial instruments: cash and cash equivalents, investments, receivables, accounts payable, medical benefits payable, long-term debt and other liabilities. We consider the carrying amounts of cash and cash equivalents, receivables, other current assets and current liabilities to approximate their fair value due to the short period of time between the origination of these instruments and the expected realization or payment.
	Recurring Fair Value Measurements
	Assets and liabilities measured at fair value on a recurring basis at March 31, 2015 are as follows:
				Fair Value Measurements Using
		Carrying Value		Quoted Prices in		Significant Other		Significant
				Active Markets		Observable		Unobservable
				for Identical		Inputs		Inputs
				Assets		(Level 2)		(Level 3)
				(Level 1)
	Investments:
	Asset backed securities	$	22.5	$	—	$	22.5	$	—
	Auction rate securities	32.3		—		—		32.3
	Corporate debt securities	136.9		—		136.9		—
	Money market funds	41.4		41.4		—		—
	Municipal securities	88		—		88		—
	U.S. government and agency obligations	16.5		11.9		4.6		—
	Variable rate bond fund	85		85		—		—
	Total investments	$	422.6	$	138.3	$	252	$	32.3
	Restricted investments:
	Cash	64.1		64.1		—		—
	Certificates of deposit	1.1		—		1.1		—
	Money market funds	65.8		65.8		—		—
	U.S. government and agency obligations	31.5		31.5		—		—
	Total restricted investments	$	162.5	$	161.4	$	1.1	$	—
	Assets and liabilities measured at fair value on a recurring basis at December 31, 2014 are as follows:
				Fair Value Measurements Using
		Carrying Value		Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
				(Level 1)		(Level 2)		(Level 3)
	Investments:
	Asset backed securities	$	23.3	$	—	$	23.3	$	—
	Auction rate securities	32.3		—		—		32.3
	Certificates of deposit	0.3		—		0.3		—
	Corporate debt securities	138.6		—		138.6		—
	Money market funds	41.4		41.4		—		—
	Municipal securities	87.3		—		87.3		—
	U.S. government securities	21.7		16.8		4.9		—
	Variable rate bond fund	85.2		85.2		—		—
	Total investments	$	430.1	$	143.4	$	254.4	$	32.3
	Restricted investments:
	Cash	$	53.3	$	53.3	$	—	$	—
	Certificates of deposit	1		—		1		—
	Money market funds	65.9		65.9		—		—
	U.S. government securities	30.1		30.1		—		—
	Total restricted investments	$	150.3	$	149.3	$	1	$	—
	Amounts accrued related to investigation resolution	$	35.2	$	—	$	35.2	$	—
	The following table presents the carrying value and fair value of our Senior Notes and Term Loan as of March 31, 2015 and December 31, 2014:
		March 31, 2015		December 31, 2014
	Long term debt	$	900	$	900
	Approximate fair value of our long-term debt	923.2		908.7
	The fair value of our Senior Notes was determined based on quoted market prices and therefore would be classified within Level 1 of the fair value hierarchy. The fair value of our Term Loan was determined based on a discounted cash flow analysis, and therefore would be classified within Level 2 of the fair value hierarchy.
	The following table presents the changes in the fair value of our Level 3 auction rate securities for the three months ended March 31, 2015.
	Balance as of January 1, 2015	$	32.3
	Realized gains (losses) in earnings	—
	Unrealized gains (losses) in other comprehensive income	—
	Purchases, sales and redemptions	—
	Net transfers in or (out) of Level 3	—
	Balance as of March 31, 2015	$	32.3

INCOME_TAXES

INCOME TAXES	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES
	Our effective income tax rate for the three months ended March 31, 2015 was 67.8% compared to 32.8% for the same period in 2014. The higher 2015 effective rate reflects the impact of higher non-deductible ACA industry fees compared to 2014. Additionally, the 2014 rate reflects a favorable impact from the Windsor bargain purchase gain.
	In September 2014, the Internal Revenue Service ("IRS") issued final regulations on the ACA's $0.5 million limit on the deduction for compensation for health insurance providers under Code section 162(m)(6). As a result, we no longer believe the deduction limitations apply to WellCare, and we took deductions totaling $1.3 million for such compensation during the three months ended March 31, 2015. However, we are not able to conclude at this time that our tax position is more likely than not to be sustained upon IRS review. Therefore, we have recognized a cumulative liability for unrecognized tax benefits amounting to $11.7 million at March 31, 2015, which includes $10.4 million of previously recorded tax expense from prior periods which we reversed in 2014. The unrecognized tax benefit, if recognized, would reduce the effective tax rate.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES
	Government Investigations
	Under the terms of settlement agreements entered into on April 26, 2011, and finalized on March 23, 2012, to resolve matters under investigation by the Civil Division of the U.S. Department of Justice ("Civil Division") and certain other federal and state enforcement agencies (the "Settlement"), we agreed to pay the Civil Division a total of $137.5 million in four annual installments of $34.4 million over 36 months, plus interest accrued at 3.125%. The final payment of $35.4 million, which included accrued interest, was remitted to the Civil Division in March 2015. As of March 31, 2015, no amounts remain outstanding related to this obligation.
	Securities Class Action Complaint
	In December 2010, we entered into a Stipulation and Agreement of Settlement (the "Stipulation Agreement") with the lead plaintiffs in the consolidated securities class action Eastwood Enterprises, L.L.C. v. Farha, et al., Case No. 8:07-cv-1940-VMC-EAJ. The Stipulation Agreement requires us to pay to the class 25% of any sums we recover from Todd Farha, Paul Behrens and/or Thaddeus Bereday related to the same facts and circumstances that gave rise to the consolidated securities class action. Messrs. Farha, Behrens and Bereday are three former executives that were implicated in the government investigations of the Company that commenced in 2007.
	Corporate Integrity Agreement
	We operate under a Corporate Integrity Agreement (the "Corporate Integrity Agreement") with the Office of Inspector General of the United States Department of Health and Human Services ("OIG-HHS"). The Corporate Integrity Agreement has a term of five years from its effective date of April 26, 2011 and mandates various ethics and compliance programs designed to help ensure our ongoing compliance with federal health care program requirements. The terms of the Corporate Integrity Agreement include certain organizational structure requirements, internal monitoring requirements, compliance training, screening processes for associates, requirements related to reporting to OIG-HHS, and the engagement of an independent review organization to review and prepare written reports regarding, among other things, WellCare's reporting practices and bid submissions to federal health care programs. If we do not comply with the terms of the Corporate Integrity Agreement, we may be subject to penalties or exclusion from participation in federal health care programs.
	Indemnification Obligations
	Under Delaware law, our charter and bylaws and certain indemnification agreements to which we are a party, we are obligated to indemnify, or we have otherwise agreed to indemnify, certain of our current and former directors, officers and associates with respect to current and future investigations and litigation, including the matters discussed in this note. The indemnification agreements for our directors and executive officers with respect to events occurring prior to May 2009 require us to indemnify an indemnitee to the fullest extent permitted by law if the indemnitee was or is or becomes a party to or a witness or other participant in any proceeding by reason of any event or occurrence related to the indemnitee's status as a director, officer, associate, agent or fiduciary of the Company or any of our subsidiaries and all expenses, including attorney's fees, judgments, fines, settlement amounts and interest and other charges, and any taxes as a result of the receipt of payments under the indemnification agreement. We will not indemnify the indemnitee if not permitted under applicable law. We are required to advance all expenses incurred by the indemnitee. We are entitled to reimbursement by an indemnitee of expenses advanced if the indemnitee is not permitted to be reimbursed under applicable law after a final judicial determination is made and all rights of appeal have been exhausted or lapsed.
	We amended and restated our indemnification agreements in May 2009. The revised agreements apply to our officers and directors with respect to events occurring after that time. Pursuant to the 2009 indemnification agreements, we will indemnify the indemnitee against all expenses, including attorney's fees, judgments, penalties, fines, settlement amounts and any taxes imposed as a result of payments made under the indemnification agreement incurred in connection with any proceedings that relate to the indemnitee's status as a director, officer or associate of the Company or any of our subsidiaries or any other enterprise that the indemnitee was serving at our request. We will also indemnify for expenses incurred by an indemnitee if the indemnitee, by reason of his or her corporate status, is a witness in any proceeding. Further, we are required to indemnify for expenses incurred by an indemnitee in defense of a proceeding to the extent the indemnitee has been successful on the merits or otherwise. Finally, if the indemnitee is involved in certain proceedings as a result of the indemnitee's corporate status, we are required to advance the indemnitee's reasonable expenses incurred in connection with such proceeding, subject to the requirement that the indemnitee repay the expenses if it is ultimately determined that the indemnitee is not entitled to be indemnified. We are not obligated to indemnify an indemnitee for losses incurred in connection with any proceeding if a determination has not been made by the Board of Directors, a committee of disinterested directors or independent legal counsel in the specific case that the indemnitee has satisfied any standards of conduct required as a condition to indemnification under Section 145 of the Delaware General Corporation Law.
	Pursuant to our obligations, we have advanced, and will continue to advance, legal fees and related expenses to three former officers and two additional associates who were criminally indicted in connection with the government investigations of the Company that commenced in 2007 related to federal criminal health care fraud charges including conspiracy to defraud the United States, false statements relating to health care matters, and health care fraud in connection with their defense of criminal charges. In June 2013, the jury in the criminal trial reached guilty verdicts on multiple charges for the four individuals that were tried in 2013. In May 2014, the individuals were sentenced and our request for restitution was denied. All four individuals filed notices of appeal and the government has filed notices of cross appeal on three of the four individuals, which the government subsequently voluntarily dismissed. The fifth individual is expected to be tried after the appeals have been decided.
	We have also previously advanced legal fees and related expenses to these five individuals regarding: disputes in Delaware Chancery Court related to whether we were legally obligated to advance fees or indemnify certain of these executives; the class actions titled Eastwood Enterprises, L.L.C. v. Farha, et al. and Hutton v. WellCare Health Plans, Inc. et al. filed in federal court; six stockholder derivative actions filed in federal and state courts between October 2007 and January 2008; an investigation by the United States Securities & Exchange Commission (the "Commission"); and an action by the Commission filed in January 2012 against three of the five individuals, Messrs. Farha, Behrens and Bereday. The Delaware Chancery Court cases have concluded. We settled the class actions in May 2011. In 2010, we settled the stockholder derivative actions and we were realigned as the plaintiff to pursue our claims against Messrs. Farha, Behrens and Bereday. These actions, as well as the action by the Commission, are currently stayed.
	In connection with these matters, we have advanced, to the five individuals, cumulative legal fees and related expenses of approximately $192.6 million from the inception of the investigations to March 31, 2015. We incurred $6.7 million and $7.8 million of these legal fees and related expenses during the quarters ended March 31, 2015 and 2014, respectively. We expense these costs as incurred and classify the costs as selling, general and administrative expense incurred in connection with the investigations and related matters.
	We expect the continuing cost of our obligations to the five individuals in connection with their defense and appeal of criminal charges and related litigation to be significant and to continue for a number of years. We have exhausted our insurance policies related to reimbursement of our advancement of fees related to these matters. We are unable to estimate the total amount of these costs or a range of possible loss. Accordingly, we continue to expense these costs as incurred. Even if it is eventually determined that we are entitled to reimbursement of the advanced expenses, it is possible that we may not be able to recover all or any portion of our damages or advances. Our indemnification obligations and requirements to advance legal fees and expenses may continue to have a material adverse effect on our financial condition, results of operations and cash flows.
	Other Lawsuits and Claims
	Based on the nature of our business, we are subject to regulatory reviews or other investigations by various state insurance and health care regulatory authorities and other state and federal regulatory authorities. These authorities regularly scrutinize the business practices of health insurance and benefits companies and their reviews focus on numerous facets of our business, including claims payment practices, provider contracting, competitive practices, commission payments, privacy issues and utilization management practices, among others. Some of these reviews have historically resulted in fines imposed on us and some have required changes to our business practices. We continue to be subject to such reviews, which may result in additional fines and/or sanctions being imposed, premium refunds or additional changes in our business practices.
	Separate and apart from the legal matters described above, we are also involved in other legal actions in the normal course of our business, including, without limitation, wage and hour claims and other employment claims, vendor disputes and provider disputes regarding payment of claims. Some of these actions seek monetary damages including claims for liquidated or punitive damages, which are not covered by insurance. We review relevant information with respect to litigation matters and we update our estimates of reasonably possible losses and related disclosures. We accrue an estimate for contingent liabilities, including attorney's fees related to these matters, if a loss is probable and estimable. Currently, we do not expect that the resolution of any currently pending actions, either individually or in the aggregate, will differ materially from our current estimates or have a material adverse effect on our results of operations, financial condition and cash flows. However, the outcome of any legal actions cannot be predicted, and therefore, actual results may differ from those estimates.

ORGANIZATION_BASIS_OF_PRESENTA1

ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Accounting	The accompanying unaudited condensed consolidated balance sheets and statements of comprehensive income, changes in stockholders' equity, and cash flows include the accounts of the Company and all of its majority-owned subsidiaries. We eliminated all intercompany accounts and transactions.
	The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. The accompanying unaudited condensed consolidated interim financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the fiscal year ended December 31, 2014 included in our Annual Report on Form 10-K, filed with the U.S. Securities and Exchange Commission in February 2015. Results for the interim periods presented are not necessarily indicative of results that may be expected for the entire year or any other interim period.
Use of Estimates	In the opinion of management, the interim financial statements reflect all normal recurring adjustments that we consider necessary for the fair presentation of our financial position, results of operations and cash flows for the interim periods presented. In accordance with GAAP, we make certain estimates and assumptions that affect the amounts reported in the condensed consolidated interim financial statements and accompanying notes. We base these estimates on our knowledge of current events and anticipated future events and evaluate and update our assumptions and estimates on an ongoing basis; however, actual results may differ from our estimates. We evaluated all material events subsequent to the date of these condensed consolidated interim financial statements.
Medical Benefits and Medical Benefits Payable	Medical Benefits and Medical Benefits Payable
	We recognize the cost of medical benefits in the period in which services are provided, including an estimate of the cost of medical benefits incurred but not reported ("IBNR"). Medical benefits expense includes direct medical expenses and certain medically-related administrative costs. We evaluate our estimates of medical benefits payable as we obtain more complete claims information and medical expense trend data over time. We record differences between actual experience and estimates used to establish the liability, which we refer to as favorable and unfavorable prior year reserve developments, as increases or decreases to medical benefits expense in the period we identify the differences.
	Favorable prior year reserve development amounted to $12.1 million for the three months ended March 31, 2015, compared to $32.5 million of unfavorable prior year reserve development recognized for the three months ended March 31, 2014. Such amounts are net of the development relating to refunds associated with minimum medical loss ratio provisions. The favorable development recognized in the three months ended March 31, 2015 was due mainly to lower than projected medical costs, while the unfavorable development recognized in 2014 was primarily due to higher than expected medical services in our Medicare Health Plan segment and to a lesser extent, the Medicaid Health Plans segment, that was not discernible until the impact became clearer over time as claim payments were processed.
ACA Industry Fee	ACA Industry Fee
	In 2014, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the "ACA") began imposing an annual premium-based health insurance industry assessment (the "ACA industry fee") on health insurers. The total ACA industry fee levied on the health insurance industry was $8 billion in 2014 and will be $11.3 billion in 2015, with increasing annual amounts thereafter, growing to $14.3 billion by 2018. After 2018, the ACA industry fee increases according to an index based on net premium growth. The ACA industry fee is not deductible for income tax purposes. For 2015, we accrued the initial estimated liability of $232.8 million as of January 1, 2015, with a corresponding deferred expense asset that is being amortized to expense on a straight line basis. We incurred approximately $58.3 million and $32.3 million of such amortization as ACA industry fee expense in the three months ended March 31, 2015 and 2014, respectively. The deferred expense asset amounted to $174.5 million at March 31, 2015 and is reported as 'Deferred ACA industry fee' on the condensed consolidated balance sheet. The 2015 final fee amount will be determined in August 2015 and our estimate is subject to change.
	We have obtained amendments, written agreements and other documentation from our Medicaid customers to reimburse us for the impact of the industry fee on our Medicaid plans for 2015, including its non-deductibility for income tax purposes.
	Consequently, we recognized $54.4 million of reimbursement for the ACA industry fee as premium revenue in the three months ended March 31, 2015, compared to $23.6 million recognized during the same period in 2014.
Recently Issued Accounting Standards	In April 2015, the Financial Accounting Standards Board ("FASB") issued ASU 2015-03, "Interest - Imputation of Interest (Subtopic 835-30) - Simplifying the Presentation of Debt Issuance Costs" to simplify the presentation of debt issuance costs by requiring debt issuance costs to be presented as a deduction from the corresponding debt liability. This will make the presentation of debt issuance costs consistent with the presentation of debt discounts or premiums. For public business entities, the final guidance will be effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. We will adopt this guidance effective January 1, 2016. We do not believe the adoption of this standard will have a material impact on our consolidated financial position, results of operations or cash flows.

SEGMENT_REPORTING_Tables

SEGMENT REPORTING (Tables)	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Revenue by geographic location	Our Medicaid operations in certain states individually account for 10% or more of our consolidated premium revenue. Those states, and the respective Medicaid premium revenue as a percentage of total consolidated premium revenue, are as follows:
		For the Three Months Ended March 31,
		2015		2014
	Kentucky	18%		17%
	Florida	16%		10%
	Georgia	12%		12%
Segment results	A summary of financial information for our reportable operating segments through the gross margin level and a reconciliation to income before income taxes is presented in the tables below.
		For the Three Months Ended March 31,
		2015			2014
	Premium revenue:	(in millions)
	Medicaid Health Plans	$	2,203.10		$	1,638.80
	Medicare Health Plans	983.4			963.3
	Medicare PDPs	279.5			373
	Total premium revenue	3,466.00			2,975.10
	Medical benefits expense:
	Medicaid Health Plans	1,917.60			1,389.30
	Medicare Health Plans	856.4			851.5
	Medicare PDPs	278.2			389.1
	Total medical benefits expense	3,052.20			2,629.90
	ACA industry fee expense:
	Medicaid Health Plans	34.8			18.9
	Medicare Health Plans	17.7			10.7
	Medicare PDPs	5.8			2.7
	Total ACA industry fee expense	58.3			32.3
	Gross margin
	Medicaid Health Plans	250.7			230.6
	Medicare Health Plans	109.3			101.1
	Medicare PDPs	(4.5		)	(18.8		)
	Total gross margin	355.5			312.9
	Investment and other income	3.9			10.6
	Other expenses	(305.0		)	(286.2		)
	Income from operations	$	54.4		$	37.3

NET_INCOME_PER_COMMON_SHARE_Ta

NET INCOME PER COMMON SHARE (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Schedule of net income per share	The calculation of the weighted-average common shares outstanding — diluted is as follows:
		For the Three Months Ended March 31,
		2015	2014
	Weighted-average common shares outstanding — basic	43,981,977	43,802,047
	Dilutive effect of:
	Unvested RSUs, MSUs and PSUs	319,662	308,133
	Stock options	2,367	13,611
	Weighted-average common shares outstanding — diluted	44,304,006	44,123,791
	Anti-dilutive stock options, RSUs, MSUs and PSUs excluded from computation	3,520	72,457

INVESTMENTS_Tables

INVESTMENTS (Tables)	3 Months Ended
	Mar. 31, 2015
Investments, Debt and Equity Securities [Abstract]
Available-for-sale investments	The amortized cost, gross unrealized gains or losses and estimated fair value of short-term and long-term investments by security type are summarized in the following tables.
		Amortized		Gross		Gross			Estimated
		Cost		Unrealized		Unrealized			Fair Value
				Gains		Losses
	March 31, 2015
	Auction rate securities	$	34.1	$	—	$	(1.8	)	$	32.3
	Corporate debt and other securities	159.2		0.4		(0.2		)	159.4
	Money market funds	41.4		—		—			41.4
	Municipal securities	87.6		0.5		(0.1		)	88
	Variable rate bond fund	85.1		0.1		(0.2		)	85
	U.S. government securities	16.5		0.1		(0.1		)	16.5
		$	423.9	$	1.1	$	(2.4	)	$	422.6
	December 31, 2014
	Auction rate securities	$	34.1	$	—	$	(1.8	)	$	32.3
	Certificates of deposit	0.3		—		—			0.3
	Corporate debt and other securities	162.2		0.1		(0.4		)	161.9
	Money market funds	41.4		—		—			41.4
	Municipal securities	86.9		0.5		(0.1		)	87.3
	Variable rate bond fund	85.1		0.2		(0.1		)	85.2
	U.S. government securities	21.7		0.1		(0.1		)	21.7
		$	431.7	$	0.9	$	(2.5	)	$	430.1
Contractual maturities of available-for-sale investments	Contractual maturities of available-for-sale investments at March 31, 2015 are as follows:
		Total		Within		1 Through 5			5 Through 10		Thereafter
				1 Year		Years			Years
	Auction rate securities	$	32.3	$	—	$	—		$	—	$	32.3
	Corporate debt and other securities	159.4		60.9		97.7			0.3		0.5
	Money market funds	41.4		41.4		—			—		—
	Municipal securities	88		18.6		56.8			11.1		1.5
	Variable rate bond fund	85		85		—			—		—
	U.S. government securities	16.5		1.2		15.3			—		—
		$	422.6	$	207.1	$	169.8		$	11.4	$	34.3

RESTRICTED_INVESTMENTS_Tables

RESTRICTED INVESTMENTS (Tables)	3 Months Ended
	Mar. 31, 2015
Restricted Investments Note [Abstract]
Schedule of Restricted Investments	The amortized cost, gross unrealized gains, gross unrealized losses and fair value of our restricted investment securities are as follows:
		Amortized		Gross		Gross			Estimated
		Cost		Unrealized		Unrealized			Fair Value
				Gains		Losses
	March 31, 2015
	Cash	$	64.1	$	—	$	—		$	64.1
	Certificates of deposit	1.1		—		—			1.1
	Money market funds	65.8		—		—			65.8
	U.S. government securities	31.4		0.1		—			31.5
		$	162.4	$	0.1	$	—		$	162.5
	December 31, 2014
	Cash	$	53.3	$	—	$	—		$	53.3
	Certificates of deposit	1		—		—			1
	Money market funds	65.9		—		—			65.9
	U.S. government securities	30.1		0.1		(0.1		)	30.1
		$	150.3	$	0.1	$	(0.1	)	$	150.3

EQUITYBASED_COMPENSATION_Table

EQUITY-BASED COMPENSATION (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of stock option activity	A summary of stock option activity for the three months ended March 31, 2015 is presented in the table below.
		Shares		Weighted
				Average
				Exercise
				Price
	Outstanding as of January 1, 2015	8,020		$	38.92
	Granted	—		—
	Exercised	(8,020	)	38.92
	Forfeited and expired	—		—
	Outstanding as of March 31, 2015	—		$	—
Summary of restricted stock and restricted stock unit activity	A summary of RSU, PSU and MSU award activity for the three months ended March 31, 2015 is presented in the table below.
		RSUs		PSUs		MSUs		Total
	Outstanding as of January 1, 2015	406,903		395,075		113,663		915,641
	Granted	3,520		—		9,361		12,881
	Vested	(128,145	)	(18,548	)	(32,494	)	(179,187	)
	Forfeited and expired	(11,378	)	(75,253	)	(7,022	)	(93,653	)
	Outstanding as of March 31, 2015	270,900		301,274		83,508		655,682

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Assets and liabilities measured at fair value	Assets and liabilities measured at fair value on a recurring basis at March 31, 2015 are as follows:
				Fair Value Measurements Using
		Carrying Value		Quoted Prices in		Significant Other		Significant
				Active Markets		Observable		Unobservable
				for Identical		Inputs		Inputs
				Assets		(Level 2)		(Level 3)
				(Level 1)
	Investments:
	Asset backed securities	$	22.5	$	—	$	22.5	$	—
	Auction rate securities	32.3		—		—		32.3
	Corporate debt securities	136.9		—		136.9		—
	Money market funds	41.4		41.4		—		—
	Municipal securities	88		—		88		—
	U.S. government and agency obligations	16.5		11.9		4.6		—
	Variable rate bond fund	85		85		—		—
	Total investments	$	422.6	$	138.3	$	252	$	32.3
	Restricted investments:
	Cash	64.1		64.1		—		—
	Certificates of deposit	1.1		—		1.1		—
	Money market funds	65.8		65.8		—		—
	U.S. government and agency obligations	31.5		31.5		—		—
	Total restricted investments	$	162.5	$	161.4	$	1.1	$	—
	Assets and liabilities measured at fair value on a recurring basis at December 31, 2014 are as follows:
				Fair Value Measurements Using
		Carrying Value		Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
				(Level 1)		(Level 2)		(Level 3)
	Investments:
	Asset backed securities	$	23.3	$	—	$	23.3	$	—
	Auction rate securities	32.3		—		—		32.3
	Certificates of deposit	0.3		—		0.3		—
	Corporate debt securities	138.6		—		138.6		—
	Money market funds	41.4		41.4		—		—
	Municipal securities	87.3		—		87.3		—
	U.S. government securities	21.7		16.8		4.9		—
	Variable rate bond fund	85.2		85.2		—		—
	Total investments	$	430.1	$	143.4	$	254.4	$	32.3
	Restricted investments:
	Cash	$	53.3	$	53.3	$	—	$	—
	Certificates of deposit	1		—		1		—
	Money market funds	65.9		65.9		—		—
	U.S. government securities	30.1		30.1		—		—
	Total restricted investments	$	150.3	$	149.3	$	1	$	—
	Amounts accrued related to investigation resolution	$	35.2	$	—	$	35.2	$	—
Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]	The following table presents the carrying value and fair value of our Senior Notes and Term Loan as of March 31, 2015 and December 31, 2014:
		March 31, 2015		December 31, 2014
	Long term debt	$	900	$	900
	Approximate fair value of our long-term debt	923.2		908.7
	The fair value of our Senior Notes was determined based on quoted market prices and therefore would be classified within Level 1 of the fair value hierarchy. The fair value of our Term Loan was determined based on a discounted cash flow analysis, and therefore would be classified within Level 2 of the fair value hierarchy.
Auction rate securities measured at fair value on a recurring basis using significant unobservable inputs	The following table presents the changes in the fair value of our Level 3 auction rate securities for the three months ended March 31, 2015.
	Balance as of January 1, 2015	$	32.3
	Realized gains (losses) in earnings	—
	Unrealized gains (losses) in other comprehensive income	—
	Purchases, sales and redemptions	—
	Net transfers in or (out) of Level 3	—
	Balance as of March 31, 2015	$	32.3

ORGANIZATION_BASIS_OF_PRESENTA2

ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - Organizational Details (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
	Members
	State
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of members	3,800,000
Number of states	49
Net favorable development, impact on medical expense	$12.10
Net unfavorable development, impact on medical expense		$32.50

ORGANIZATION_BASIS_OF_PRESENTA3

ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES - ACA Industry Fee (Details) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Affordable Care Act levied on health insurance industry	$11,300,000,000		$8,000,000,000
Expected annual fees for Affordable Care Act levied on health industry, by 2018	14,300,000,000
ACA industry fee	232,800,000		0
Deferred ACA fee amortization	58,300,000	32,300,000
Deferred ACA industry fee asset	174,500,000		0
Premium revenue, fee reimbursement	$54,400,000	$23,600,000

ACQUISITIONS_Details

ACQUISITIONS (Details) (USD $)	3 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Jan. 02, 2014
Business Acquisition [Line Items]
Bargain purchase gain	$0	$28.30
Windsor Health Plans, Inc.
Business Acquisition [Line Items]
Premium revenue of acquiree since acquisition date	144	167.6
Purchase price allocated to identified intangible assets				54.3
Bargain purchase gain		28.3	29.5
Tangible Assets and Liabilities | Windsor Health Plans, Inc.
Business Acquisition [Line Items]
Fair value of net tangible assets acquired				$195.30
Weighted Average | Windsor Health Plans, Inc.
Business Acquisition [Line Items]
Weighted average amortization period for intangible assets	11 years 6 months

SEGMENT_REPORTING_Details

SEGMENT REPORTING (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
	Segment
Segment Reporting Information [Line Items]
Number of reportable segments	3
Premium revenue	$3,466	$2,975.10
Medical benefits expense	3,052.20	2,629.90
ACA industry fee expense	58.3	32.3
Gross margin	355.5	312.9
Investment and other income	3.9	10.6
Other expenses	-305	-286.2
Income from operations	54.4	37.3
Medicaid Health Plans
Segment Reporting Information [Line Items]
Premium revenue	2,203.10	1,638.80
Medical benefits expense	1,917.60	1,389.30
ACA industry fee expense	34.8	18.9
Gross margin	250.7	230.6
Medicare Health Plans
Segment Reporting Information [Line Items]
Premium revenue	983.4	963.3
Medical benefits expense	856.4	851.5
ACA industry fee expense	17.7	10.7
Gross margin	109.3	101.1
Medicare PDPs
Segment Reporting Information [Line Items]
Premium revenue	279.5	373
Medical benefits expense	278.2	389.1
ACA industry fee expense	5.8	2.7
Gross margin	($4.50)	($18.80)
Kentucky
Segment Reporting Information [Line Items]
Premium revenue net of premium tax (as a percent)	18.00%	17.00%
Initial term of short-term contracts	3 years
Number of renewal options	4
Term of optional renewals	1 year
Florida
Segment Reporting Information [Line Items]
Premium revenue net of premium tax (as a percent)	16.00%	10.00%
Number of Regions executed contracts	8
Total number of regions	11
Georgia
Segment Reporting Information [Line Items]
Premium revenue net of premium tax (as a percent)	12.00%	12.00%
Number of renewal options	1
Term of optional renewals	1 year
Minimum
Segment Reporting Information [Line Items]
Percentage of consolidated premium revenue	10.00%

NET_INCOME_PER_COMMON_SHARE_De

NET INCOME PER COMMON SHARE (Details)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Earnings Per Share [Abstract]
Weighted-average common shares outstanding b basic	43,981,977	43,802,047
Dilutive effect of:
Unvested RSUs, MSUs and PSUs	319,662	308,133
Stock options	2,367	13,611
Weighted-average common shares outstanding b diluted	44,304,006	44,123,791
Anti-dilutive stock options, RSUs, MSUs and PSUs excluded from computation	3,520	72,457

INVESTMENTS_Details

INVESTMENTS (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$423,900,000		$431,700,000
Gross Unrealized Gains	1,100,000		900,000
Gross Unrealized Losses	-2,400,000		-2,500,000
Estimated Fair Value	422,600,000		430,100,000
Within 1 Year	207,100,000
1 Through 5 Years	169,800,000
5 Through 10 Years	11,400,000
Thereafter	34,300,000
Auction rate securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	34,100,000		34,100,000
Gross Unrealized Gains	0		0
Gross Unrealized Losses	-1,800,000		-1,800,000
Estimated Fair Value	32,300,000		32,300,000
Within 1 Year	0
1 Through 5 Years	0
5 Through 10 Years	0
Thereafter	32,300,000
Redemptions or sales	0	0
Certificates of deposit
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost			300,000
Gross Unrealized Gains			0
Gross Unrealized Losses			0
Estimated Fair Value			300,000
Corporate debt and other securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	159,200,000		162,200,000
Gross Unrealized Gains	400,000		100,000
Gross Unrealized Losses	-200,000		-400,000
Estimated Fair Value	159,400,000		161,900,000
Within 1 Year	60,900,000
1 Through 5 Years	97,700,000
5 Through 10 Years	300,000
Thereafter	500,000
Money market funds
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	41,400,000		41,400,000
Gross Unrealized Gains	0		0
Gross Unrealized Losses	0		0
Estimated Fair Value	41,400,000		41,400,000
Within 1 Year	41,400,000
1 Through 5 Years	0
5 Through 10 Years	0
Thereafter	0
Municipal securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	87,600,000		86,900,000
Gross Unrealized Gains	500,000		500,000
Gross Unrealized Losses	-100,000		-100,000
Estimated Fair Value	88,000,000		87,300,000
Within 1 Year	18,600,000
1 Through 5 Years	56,800,000
5 Through 10 Years	11,100,000
Thereafter	1,500,000
Variable rate bond fund
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	85,100,000		85,100,000
Gross Unrealized Gains	100,000		200,000
Gross Unrealized Losses	-200,000		-100,000
Estimated Fair Value	85,000,000		85,200,000
Within 1 Year	85,000,000
1 Through 5 Years	0
5 Through 10 Years	0
Thereafter	0
U.S. government securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	16,500,000		21,700,000
Gross Unrealized Gains	100,000		100,000
Gross Unrealized Losses	-100,000		-100,000
Estimated Fair Value	16,500,000		21,700,000
Within 1 Year	1,200,000
1 Through 5 Years	15,300,000
5 Through 10 Years	0
Thereafter	0
External Credit Rating, Investment Grade | Auction rate securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	22,500,000
Number of securities	2
External Credit Rating, Non Investment Grade | Auction rate securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$11,600,000
Number of securities	1
Minimum | Auction rate securities
Schedule of Available-for-sale Securities [Line Items]
Rate setting interval for sale	7 days
Maximum | Auction rate securities
Schedule of Available-for-sale Securities [Line Items]
Rate setting interval for sale	35 days

RESTRICTED_INVESTMENTS_Details

RESTRICTED INVESTMENTS (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	$162.40	$150.30
Gross Unrealized Gains	0.1	0.1
Gross Unrealized Losses	0	-0.1
Estimated Fair Value	162.5	150.3
Cash
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	64.1	53.3
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value	64.1	53.3
Certificates of deposit
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	1.1	1
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value	1.1	1
Money market funds
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	65.8	65.9
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value	65.8	65.9
U.S. government securities
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	31.4	30.1
Gross Unrealized Gains	0.1	0.1
Gross Unrealized Losses	0	-0.1
Estimated Fair Value	$31.50	$30.10

EQUITYBASED_COMPENSATION_Detai

EQUITY-BASED COMPENSATION (Details) (USD $)	3 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense	$4.10	$1.20
Unrecognized compensation cost	22.5
Weighted-average period over which compensation costs are expected to be recognized (in years)	1 year 7 months
Share price	$91.46
Equity Instruments Other than Options [Roll Forward]
Outstanding as of beginning of period (in shares)	915,641
Granted (in shares)	12,881
Vested (in shares)	-179,187
Forfeited and expired (in shares)	-93,653
Outstanding at end of period (in shares)	655,682
Grants in period, weighted average grant date fair value	$77.79
Stock Options
Stock Options [Rollforward]
Outstanding as of beginning of period (in shares)	8,020
Granted (in shares)	0
Exercised (in shares)	-8,020
Forfeited and expired (in shares)	0
Outstanding at end of period (in shares)	0
Weighted Average Exercise Price [Rollforward]
Outstanding as of beginning of period (in dollars per share)	$38.92
Granted (in dollars per share)	$0
Exercised (in dollars per share)	$38.92
Forfeited and expired (in dollars per share)	$0
Outstanding at end of period (in dollars per share)	$0
RSUs
Equity Instruments Other than Options [Roll Forward]
Outstanding as of beginning of period (in shares)	406,903
Granted (in shares)	3,520
Vested (in shares)	-128,145
Forfeited and expired (in shares)	-11,378
Outstanding at end of period (in shares)	270,900
PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$10.70
Equity Instruments Other than Options [Roll Forward]
Outstanding as of beginning of period (in shares)	395,075
Granted (in shares)	0
Vested (in shares)	-18,548
Forfeited and expired (in shares)	-75,253
Outstanding at end of period (in shares)	301,274
MSUs
Equity Instruments Other than Options [Roll Forward]
Outstanding as of beginning of period (in shares)	113,663
Granted (in shares)	9,361
Vested (in shares)	-32,494
Forfeited and expired (in shares)	-7,022
Outstanding at end of period (in shares)	83,508

DEBT_Details

DEBT (Details) (USD $)	3 Months Ended
	Mar. 31, 2015
Debt Instrument [Line Items]
Revolving credit facility, maximum borrowing capacity	$300,000,000
Minimum statutory net worth	105.00%
Minimum percent of loans and commitments owned under credit agreement required to accelerate maturity	50.00%
Term Loan
Debt Instrument [Line Items]
Long-term debt	300,000,000
Senior Notes
Debt Instrument [Line Items]
Long-term debt	$600,000,000
Interest rate	5.75%
Term Loan
Debt Instrument [Line Items]
Interest rate at period end (effective percentage)	2.25%
Revolving Credit Facility | Minimum
Debt Instrument [Line Items]
Unutilized commitments fee, minimum (in hundredths)	0.25%
Revolving Credit Facility | Maximum
Debt Instrument [Line Items]
Unutilized commitments fee, minimum (in hundredths)	0.45%
London Interbank Offered Rate (LIBOR) | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	1.50%
London Interbank Offered Rate (LIBOR) | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	2.63%
Prime Rate | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	0.50%
Prime Rate | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	1.63%

FAIR_VALUE_MEASUREMENTS_Detail

FAIR VALUE MEASUREMENTS (Details) (Fair Value, Measurements, Recurring [Member], USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	$422.60	$430.10
Total restricted investments	162.5	150.3
Amounts payable related to investigation resolution		35.2
Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	22.5	23.3
Auction rate securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	32.3	32.3
Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments		0.3
Total restricted investments	1.1	1
Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	136.9	138.6
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	41.4	41.4
Total restricted investments	65.8	65.9
Municipal securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	88	87.3
Variable rate bond fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	85	85.2
U.S. Government Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	16.5	21.7
Total restricted investments	31.5	30.1
Cash
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total restricted investments	64.1	53.3
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	138.3	143.4
Total restricted investments	161.4	149.3
Amounts payable related to investigation resolution		0
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Auction rate securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments		0
Total restricted investments	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	41.4	41.4
Total restricted investments	65.8	65.9
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Municipal securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Variable rate bond fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	85	85.2
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | U.S. Government Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	11.9	16.8
Total restricted investments	31.5	30.1
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Cash
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total restricted investments	64.1	53.3
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	252	254.4
Total restricted investments	1.1	1
Amounts payable related to investigation resolution		35.2
Fair Value, Inputs, Level 2 [Member] | Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	22.5	23.3
Fair Value, Inputs, Level 2 [Member] | Auction rate securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	0	0
Fair Value, Inputs, Level 2 [Member] | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments		0.3
Total restricted investments	1.1	1
Fair Value, Inputs, Level 2 [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	136.9	138.6
Fair Value, Inputs, Level 2 [Member] | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	0	0
Total restricted investments	0	0
Fair Value, Inputs, Level 2 [Member] | Municipal securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	88	87.3
Fair Value, Inputs, Level 2 [Member] | Variable rate bond fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	0	0
Fair Value, Inputs, Level 2 [Member] | U.S. Government Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	4.6	4.9
Total restricted investments	0	0
Fair Value, Inputs, Level 2 [Member] | Cash
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total restricted investments	0	0
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	32.3	32.3
Total restricted investments	0	0
Amounts payable related to investigation resolution		0
Significant Unobservable Inputs (Level 3) [Member] | Asset-backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	0	0
Significant Unobservable Inputs (Level 3) [Member] | Auction rate securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	32.3	32.3
Auction rate securities measured at fair value on a recurring basis using significant unobservable inputs [Rollforward]
Beginning balance	32.3
Realized gains (losses) in earnings	0
Unrealized gains (losses) in other comprehensive income	0
Purchases, sales and redemptions	0
Net transfers in or (out) of Level 3	0
Ending balance	32.3
Significant Unobservable Inputs (Level 3) [Member] | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments		0
Total restricted investments	0	0
Significant Unobservable Inputs (Level 3) [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	0	0
Significant Unobservable Inputs (Level 3) [Member] | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	0	0
Total restricted investments	0	0
Significant Unobservable Inputs (Level 3) [Member] | Municipal securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	0	0
Significant Unobservable Inputs (Level 3) [Member] | Variable rate bond fund
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	0	0
Significant Unobservable Inputs (Level 3) [Member] | U.S. Government Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total investments	0	0
Total restricted investments	0	0
Significant Unobservable Inputs (Level 3) [Member] | Cash
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total restricted investments	$0	$0

FAIR_VALUE_MEASUREMENTS_Fair_V

FAIR VALUE MEASUREMENTS - Fair Value of Debt (Details) (Senior Notes, USD $)	Mar. 31, 2015	Dec. 31, 2014
Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Face Amount	$900,000,000	$900,000,000
Long-term Debt, Fair Value	$923,200,000	$908,700,000

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Effective income tax rate (in hundredths)	67.80%	32.80%
Compensation deduction	$1.30
Unrecognized tax benefits	$11.70		$10.40

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	3 Months Ended	0 Months Ended	3 Months Ended	99 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 23, 2012	Mar. 31, 2014	Mar. 31, 2015	Dec. 31, 2010	Jan. 31, 2012
	associate	Installment		former_officer		former_officer
				person
				associate
				Action
Loss Contingencies [Line Items]
Final payment under settlement agreement	$35.40
Number of former associates tried in 2013	4
Civil Inquiry
Loss Contingencies [Line Items]
Settlement agreement, amount		137.5
Number of installments		4
Settlement agreement, amount of installment payments		34.4
Term of agreement	36 months
Settlement agreement, interest rate		3.13%
Class Action Complaints
Loss Contingencies [Line Items]
Portion of sums recovered from former officers to be paid to class members					25.00%
Corporate Integrity Agreement
Loss Contingencies [Line Items]
Term of agreement	5 years
Derivative Lawsuits
Loss Contingencies [Line Items]
Number of former officers being pursued in action filed by entity	3			3
Number of former associates being pursued in action filed by entity	2			2
Number of former employees being pursued in action filed by entity	5			5
Number of actions filed in the Federal Court	6			6
Number Of former employees investigated by SEC						3
Legal fees	$6.70		$7.80	$192.60